Vaccine against hepatitis a comprising simian HAV isolate AGM-27
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsSergie A. Tsarev, Suzanne U. Emerson, Michael S. Balayan, Robert H. Purcell
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
Claims6
A pharmaceutical composition comprising simian hepatitis A vital isolate AGM-27 in an amount effective to provide humans or apes with protective immunity to hepatitis A, and a pharmaceutically acceptable diluent, carrier or excipient.
A method for preventing hepatitis A in humans or apes comprising administering to said humans or apes simian hepatitis A vital isolate AGM-27.
A vaccine comprising simian hepatitis A vital isolate AGM-27 in an amount effective to provide.
A method of producing antibodies to hepatitis A virus in an animal comprising administering to said animal simian hepatitis A viral isolate AGM-27.
A pharmaceutical composition comprising simian hepatitis A viral isolate AGM-27 where said isolate is in an amount effective to produce antibodies to hepatitis A in an animal, and a pharmaceutically acceptable diluent, carrier or excipient.
Dependencies are inferred from the claim text.